Display options
Cite
Thakkar VT, Deshmukh A, Hingorani L, et al. Development and Optimization of Dispersible Tablet of . J Pharm Bioallied Sci. 2017;9(3):208-215doi: 10.4103/jpbs.JPBS_8_17.
Thakkar, V. T., Deshmukh, A., Hingorani, L., Juneja, P., Baldaniya, L., Patel, A., Pandya, T., & Gohel, M. (2017). Development and Optimization of Dispersible Tablet of . Journal of pharmacy & bioallied sciences, 9(3), 208-215. https://doi.org/10.4103/jpbs.JPBS_8_17
Thakkar, Vaishali Tejas, et al. "Development and Optimization of Dispersible Tablet of ." Journal of pharmacy & bioallied sciences vol. 9,3 (2017): 208-215. doi: https://doi.org/10.4103/jpbs.JPBS_8_17
Thakkar VT, Deshmukh A, Hingorani L, Juneja P, Baldaniya L, Patel A, Pandya T, Gohel M. Development and Optimization of Dispersible Tablet of . J Pharm Bioallied Sci. 2017 Jul-Sep;9(3):208-215. doi: 10.4103/jpbs.JPBS_8_17. PMID: 28979076; PMCID: PMC5621184.
Copy Download .nbib Format: NLM
Share it on

J Pharm Bioallied Sci. 2017 Jul-Sep;9(3):208-215. doi: 10.4103/jpbs.JPBS_8_17.

Development and Optimization of Dispersible Tablet of .

Journal of pharmacy & bioallied sciences

Vaishali Tejas Thakkar, Amol Deshmukh, Lal Hingorani, Payal Juneja, Lalji Baldaniya, Asha Patel, Tosha Pandya, Mukesh Gohel

Affiliations

  1. Department of Pharmaceutics, Anand Pharmacy College, Anand, Gujarat, India.
  2. Department of Formulation Development, Pharmanza Herbals Pvt. Ltd., Anand, Gujarat, India.
  3. Department of Pharmaceutics, Parul Institute of Pharmacy, Vadodara, Gujarat, India.

PMID: 28979076 PMCID: PMC5621184 DOI: 10.4103/jpbs.JPBS_8_17

Abstract

INTRODUCTION: The

OBJECTIVE: Poor solubility, patient compliance and bitterness were a major driving force to develop taste masked β-cyclodextrin complex and dispersible tablets.

MATERIALS AND METHODS: The inclusion complex of

CONCLUSION: The result revels that molar ratio (1:4) of inclusion complex enhance 3-fold solubility. Full factorial design was successfully employed for the optimization of dispersible tablet of

Keywords: Bacopa monnieri; dispersible tablet; memory enhancer; β-cyclodextrin

Conflict of interest statement

There are no conflicts of interest.

References

  1. Pharmazie. 2003 Sep;58(9):639-41 - PubMed
  2. Int J Pharm Investig. 2014 Jan;4(1):27-31 - PubMed
  3. AAPS PharmSciTech. 2008;9(1):314-21 - PubMed
  4. Food Chem. 2014 Jun 15;153:361-70 - PubMed
  5. Phytochemistry. 1996 Jun;42(3):815-20 - PubMed
  6. Cardiopulm Phys Ther J. 2009 Sep;20(3):23-6 - PubMed
  7. J Young Pharm. 2011 Jul;3(3):205-10 - PubMed

Publication Types